Overall, a single low dose anti-CD20 pre-treatment may effectively enhance the proliferation and accumulation of CAR-T cells at viral reservoir sites, but this treatment requires inclusion of IL-6 inhibitors to prevent CRS, and further optimization of CAR-T cells to promote long-term survival following in vivo proliferation. This evidence concerns the gene IL6 and congenital rubella syndrome.